Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 193 citing articles:

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Mark J. Levis, Mehdi Hamadani, Brent R. Logan, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 15, pp. 1766-1775
Open Access | Times Cited: 66
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
Nicholas J. Short, Naval Daver, Courtney D. DiNardo, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 13, pp. 1499-1508
Closed Access | Times Cited: 45
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 144, Iss. 7, pp. 714-728
Closed Access | Times Cited: 23
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 17
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML
Eunice S. Wang, Aaron D. Goldberg, Martin S. Tallman, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 15, pp. 1776-1787
Open Access | Times Cited: 16
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
Laura W. Dillon, Gege Gui, Niveditha Ravindra, et al.
JAMA Oncology (2024) Vol. 10, Iss. 8, pp. 1104-1104
Open Access | Times Cited: 16
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Nicholas J. Short, Daniel Nguyen, Farhad Ravandi
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 26
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Michael Wysota, Marina Konopleva, Shane Mitchell
Current Oncology Reports (2024) Vol. 26, Iss. 4, pp. 409-420
Open Access | Times Cited: 12
Advancements and Challenges in the Treatment of AML
Yasmin Abaza, Christine M. McMahon, Jacqueline S. Garcia
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches
Jaime L. Roman Diaz, Mariola Vazquez Martinez, Farhad Khimani
Cancers (2024) Vol. 16, Iss. 3, pp. 677-677
Open Access | Times Cited: 11
AML treatment: conventional chemotherapy and emerging novel agents
Mark Forsberg, Marina Konopleva
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 5, pp. 430-448
Closed Access | Times Cited: 11
Contemporary Management of Acute Myeloid Leukemia
Sangeetha Venugopal, Mikkael A. Sekeres
JAMA Oncology (2024) Vol. 10, Iss. 10, pp. 1417-1417
Closed Access | Times Cited: 11
Pathophysiology of Acute Myeloid Leukemia
Franziska Wachter, Yana Pikman
Acta Haematologica (2024) Vol. 147, Iss. 2, pp. 229-246
Closed Access | Times Cited: 10
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 10
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia
Pamela J. Sung, Murugan Selvam, Simone S. Riedel, et al.
Leukemia (2024) Vol. 38, Iss. 2, pp. 291-301
Open Access | Times Cited: 8
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
A Review of FLT3 Kinase Inhibitors in AML
Cristina Negotei, Andrei Coliţă, Iuliana Mitu, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6429-6429
Open Access | Times Cited: 21
[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)].

PubMed (2023) Vol. 44, Iss. 9, pp. 705-712
Closed Access | Times Cited: 19
Precision Oncology: 2023 in Review
Yonina R. Murciano‐Goroff, Sarah P. Suehnholz, Alexander Drilon, et al.
Cancer Discovery (2023) Vol. 13, Iss. 12, pp. 2525-2531
Open Access | Times Cited: 16
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
Boaz Nachmias, Shlomzion Aumann, Arnon Haran, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1146-1158
Open Access | Times Cited: 7
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia
Mark J. Levis, Alexander E. Perl, Gary J. Schiller, et al.
Blood Advances (2024) Vol. 8, Iss. 10, pp. 2527-2535
Open Access | Times Cited: 7
Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
Karanpreet Singh Bhatia, Vedant Sandhu, Mei Hsuan Wong, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Yi‐Ru Bai, Dong‐Jie Seng, Ying Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116706-116706
Closed Access | Times Cited: 6
Nitrogen-Containing Heterocyclic Drug Products Approved by the FDA in 2023: Synthesis and biological activity
Weijiang Luo, Yiqi Liu, Hui Qin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116838-116838
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top